First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: A cross-sectional study

AIDS Research and Therapy

Volumn 8, Issue , 2011, Pages

  Pefura Yone, Eric W ^a,b   Betyoumin, Awa F ^c   Kengne, André P ^d   Kaze Folefack, François J ^b,e   Ngogang, Jeanne ^b,c  

^a Chest Unit of Yaounde Jamot Hospital   (Cameroon)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c Biochemistry laboratory of Yaounde University Center   (Cameroon)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e YAOUNDÉ GENERAL HOSPITAL   (Cameroon)

Author keywords

Antiretroviral therapy; Cameroon; Dyslipidemia; HIV

Indexed keywords

EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CHI SQUARE TEST; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STUDENT T TEST; TUBERCULOSIS;

EID: 80053341921     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-8-33     Document Type: Article

References (29)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-60. 10.1056/NEJM199803263381301, 9516219.
2. Kumar A, Kilaru KR, Forde S, Roach TC. Changing HIV infection-related mortality rate and causes of death among persons with HIV infection before and after the introduction of highly active antiretroviral therapy: analysis of all HIV-related deaths in Barbados, 1997-2005. J Int Assoc Physicians AIDS Care(Chic) 2006, 5:109-14.
3. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 2002, 31:1016-20. 10.1093/ije/31.5.1016, 12435777.
4. Grunfeld C. Dyslipidemia and its Treatment in HIV Infection. Top HIV Med 2010, 18:112-8.
5. Domingos H, Cunha RV, Paniago AM, Martins DM, Elkhoury EB, Souza AS. Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis 2009, 13:130-6.
6. Padmapriyadarsini C, Ramesh Kumar S, Terrin N, Narendran G, Menon PA, Ramachandran G, Subramanyan S, Venkatesan P, Wanke C, Swaminathan S. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India. Clin Infect Dis 2011, 52:540-6. 10.1093/cid/ciq195, 3060904, 21252141.
7. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M, . Working Group 2 Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008, 118:e29-35. 10.1161/CIRCULATIONAHA.107.189624, 18566319, Working Group 2.
8. Bozkurt B. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies. Cardiovasc Toxicol 2004, 4:243-60. 10.1385/CT:4:3:243, 15470272.
9. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. 2006 revision. Accessed on 10 October 2010, World Health Organization., http://www.who.int/hiv/pub/arv/adult/fr/index.html
10. Organisation Mondiale de la Santé Recommandations rapides: Traitement antirétroviral de l'infection à VIH chez l'adulte et l'adolescent. Accessed on 12 December 2011, Organisation Mondiale de la Santé., http://www.who.int/hiv/pub/arv/rapid_advice_art_fr.pdf
11. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, Kigozi A, Borkowf CB, Ndazima V, Brooks JT. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008, 47:304-11. 10.1097/QAI.0b013e31815e7453, 18398971.
12. Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J, Gougounon A, Akondé A, Adé G, Houngbé F, Girard PM. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther 2009, 14:371-80.
13. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12:255-66. 10.1080/09540120050042891, 10928201.
14. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-97. 10.1001/jama.285.19.2486, 11368702, Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults.
15. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, Sinnott JT. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005, 39:199-202.
16. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Antimicrob Chemother 2004, 53:10-4.
17. Domingos H, Cunha RV, Paniago AM, Martins DM, Elkhoury EB, Souza AS. Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis 2009, 13:130-6.
18. Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005, 6:396-402. 10.1111/j.1468-1293.2005.00325.x, 16268821.
19. Fontas E, van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P, . D:A:D Study Group Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis 2004, 189:1056-74. 10.1086/381783, 14999610, D:A:D Study Group.
20. Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC. Lipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005, 10:585-91.
21. Almeida SE, Borges M, Fiegenbaum M, Nunes CC, Rossetti ML. Metabolic changes associated with antiretroviral therapy in HIV-positive patients. Rev Saude Publica 2009, 43:283-90. 10.1590/S0034-89102009005000005, 19225696.
22. Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio Monforte A, Moroni M. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002, 29:21-31.
23. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, . 903 Study Group Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201. 10.1001/jama.292.2.191, 15249568, 903 Study Group.
24. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO, Reiss P, . Atlantic Study Team Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile. AIDS 2001, 15:2407-14. 10.1097/00002030-200112070-00008, 11740191, Atlantic Study Team.
25. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral therapy-naïve patients infected with HIV. -1. PLos Med 2004, 1:e19. 10.1371/journal.pmed.0010019, 523838, 15526045.
26. Rader DJ, Hobbs HH. Disorders of lipoprotein metabolism. Harrison's principles of Internal Medicine 2005, 2294-2295. New York: Mc Graw-Hill Companies, Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Larry Jamerson J, 16, 3180698, 21954371.
27. Cahn P, Leite O, Rosales A, Cabello R, Alvarez CA, Seas C, Carcamo C, Cure-Bolt N, L'Italien GP, Mantilla P, Deibis L, Zala C, Suffert T. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. Braz J Infect Dis 2010, 14:158-66. 10.1590/S1413-86702010000200008, 20563442.
28. Nguemaïm NF, Mbuagbaw J, Nkoa T, Alemnji G, Této G, Fanhi TC, Asonganyi T, Samé-Ekobo A. Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case-control study. HIV Med 2010, 11:353-9.
29. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978-82. 10.1001/jama.289.22.2978, 12799406.